AmerisourceBergen partners with SteadyMD for telehealth solution
AmerisourceBergen is partnering with SteadyMD, a B2B telehealth infrastructure provider that powers high-quality telehealth patient experiences for leaders and innovators in health care. The two organizations have kicked off their collaboration with the cocreation of a telehealth solution focused on Test to Treat opportunities. The solution is being offered as a pilot to independent community pharmacies across the United States.
“The Test to Treat initiative is an important acknowledgement of the role of pharmacists and pharmacies as accessible healthcare providers and destinations,” said Jenni Zilka, senior vice president of Good Neighbor Pharmacy field programs and services at AmerisourceBergen.
Zilka continued, “In order for pharmacies to continue making a sustainable impact on the communities they serve, we need to continue providing them the tools, resources and authority to provide necessary clinical services, where appropriate. AmerisourceBergen’s exploration of a telehealth solution with SteadyMD to enhance the scope of the Test to Treat model is just one way we’re continuing to support the important role of the pharmacist in the healthcare ecosystem.”
[Read more: AmerisourceBergen, TPG to acquire OneOncology from General Atlantic]
AmerisourceBergen’s telehealth solution is being developed to expand the number of Tteest to Treat services independent pharmacies can offer patients. The Test to Treat initiative was launched in 2022 to help provide quick and equitable access to COVID-19 testing and treatment in the early days of infection. The model is intended to provide a seamless patient experience and is designed to reach high-risk, underserved populations.
With its telehealth solution, AmerisourceBergen is evaluating the long-term viability of the Test to Treat model for use cases beyond COVID-19 to improve access to treatment. The pilot program has been launched across a group of 130 independent retail pharmacies, including Good Neighbor Pharmacy network members.
Over a span of 12 weeks, pilot participants will utilize the SteadyMD platform to provide patients with a quick and accessible Test to Treat option within their pharmacy at an affordable price. Patients can test for an illness or condition and then, if deemed necessary by a SteadyMD physician, consult with them on demand through the telehealth platform and receive a prescription for treatment.
"We're excited to embark on a commercial partnership with AmerisourceBergen and welcome the company to our supportive family of investors," said Guy Friedman, CEO of SteadyMD. "As we continue our mission to save leaders and innovators in health care time, money and resources by helping them stand up their telehealth practices, AmerisourceBergen’s collaboration and investment will further strengthen our best-in-class technology, clinical operations and nationwide clinician workforce, while bolstering our unwavering commitment to becoming the backbone powering modern health care."
[Read more: AmerisourceBergen changes name to Cencora]
“AmerisourceBergen has an ongoing commitment to delivering innovation for its customers and aligning with organizations that are transforming health care through bold thinking, solutions and programs,” said Jason Dinger, senior vice president of global product and solutions at AmerisourceBergen. “Working with SteadyMD, we look forward to collaborating on a telehealth offering to help our pharmacy customers drive value for their patients and their bottom lines.”
Pharmacies participating in the telehealth pilot program can use the solution to help patients obtain COVID-19 oral antiviral therapies, as appropriate. AmerisourceBergen and SteadyMD will continuously evaluate opportunities to expand use cases during and after the program.
In addition to the commercial partnership, AmerisourceBergen has invested in SteadyMD through its venture fund AB Health Ventures.